Table 6. ELISA antibody titer in time-point serum samples from participants in 100 and 200 µg groups.

Dose (µg)	No. participants	ELISA titres
		Day30	Day 90	Day194	Day240
100	1	902	7,725	6,759	5,690
	2	2,419	11,071	21,373	18,920
	3	5,790	20,964	41,423	108,568
	4	3,653	3,798	12,849	11,049
	5	6,502	3,259	11,157	10,733
	6	3,798	2,097	20,246	5,369
	7	2,808	18,167	26,907	11,869
	8	1,272	2,017	2,171	2,171
	9	4,025	4,348	34,269	7,725
	10	1,455	4,025	4,183	4,689
Geomean		2,740	5,591	13,070	9,642
200	1	318	2,012	2,269	1,833
	2	3,850	111,274	71,096	74,079
	3	12,864	37,370	74,079	37,140
	4	1,216	10,539	23,391	25,447
	5	667	3,840	3,619	2,143
	6	1,891	11,003	13,294	11,004
	7	1,295	9,908	12,473	7,074
	8	5,061	11,465	28,259	28,846
	9	345	1,023	1,149	1,764
	10	2,698	15,701	18,205	ND
Geomean		1648	9621	12579	12579

Note: A: ELISA antibody titer to the PfCP-2.9 in pre-immune serum samples(Day 0) is <1∶100

B: ELISA antibody titer to the PfCP-2.9 in sera from participants receiving the placebo injection is <1∶100

C. The first vaccination was performed on day 0 and boosted vaccination were on days of 60 and 180

D. ND: not done